Coronavirus: Favipiravir to Start Clinical Trials in India

India's Council for Scientific and Industrial Research (CSIR) has received approval from India 's Drug Controller General (DGCI) for clinical trials of two drugs — Favipiravir and phytopharmaceutical for coronavirus control. Globally, several drugs are being tried to combat coronavirus. From Israel to Italy, researchers and scientists have come up with new ideas about what might be the right way to go about treating coronavirus.


What is Favipiravir?

Favipiravir, which is sold under the Avigan brand name, is an antiviral medication used in Japan and China to treat influenza. The treatment of some other viral infections is also under study. Like the experimental antiviral drugs (T-1105 and T-1106), this is a derivative of pyrazine carboxamide. Toyama Chemical (Fujifilm group) was designing and producing it and was approved for medical use in Japan in 2014. Fujifilm licenses API for it to China's Zhejiang Hisun Pharmaceutical Co. in 2016. In 2019 it developed into a generic drug.

Favipiravir (259793-96-9) was being investigated for experimental treatment of the emergentCOVID-19 in China in February 2020. A study of 80 people compared to lopinavir/ritonavir found that it decreased viral clearance time and that with little side effects, 91 percent of people had better CT scans. The study's drawback was that it was not double-blinded and placebo-controlled randomized.

The drug has been licensed to be used in coronavirus disease clinical trials in China in 2019. In March 2020, Italy approved the drug against COVID-19 for experimental use and began conducting trials in three regions most affected by the disease. However, the Italian Pharmaceutical Agency has reminded the public that the existing evidence in support of this drug is preliminary and scanty. It's planned to be studied at three Massachusetts, USA hospitals as of April 20, 2020.